Your browser is no longer supported. Please, upgrade your browser.
Settings
MORF Morphic Holding, Inc. daily Stock Chart
MORF [NASD]
Morphic Holding, Inc.
Index- P/E- EPS (ttm)-2.02 Insider Own1.10% Shs Outstand30.36M Perf Week-0.30%
Market Cap772.57M Forward P/E- EPS next Y-2.27 Insider Trans-25.35% Shs Float17.62M Perf Month5.78%
Income-61.30M PEG- EPS next Q-0.37 Inst Own61.20% Short Float4.30% Perf Quarter0.00%
Sales18.60M P/S41.54 EPS this Y-78.70% Inst Trans6.84% Short Ratio13.17 Perf Half Y83.99%
Book/sh3.79 P/B7.10 EPS next Y-22.00% ROA- Target Price34.00 Perf Year50.28%
Cash/sh7.04 P/C3.82 EPS next 5Y- ROE- 52W Range9.90 - 31.00 Perf YTD56.76%
Dividend- P/FCF- EPS past 5Y- ROI-34.00% 52W High-13.48% Beta-
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low170.91% ATR1.59
Employees76 Current Ratio4.60 Sales Q/Q37.50% Oper. Margin- RSI (14)53.40 Volatility7.37% 6.15%
OptionableNo Debt/Eq0.00 EPS Q/Q-63.90% Profit Margin- Rel Volume0.05 Prev Close26.90
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume57.49K Price26.82
Recom1.70 SMA200.40% SMA501.73% SMA20032.25% Volume600 Change-0.30%
Jul-22-19Initiated Wells Fargo Outperform
Jul-22-19Initiated Jefferies Buy
Jul-22-19Initiated Cowen Outperform
Jul-22-19Initiated BMO Capital Markets Outperform $30
Sep-28-20 10:01AM  
Sep-23-20 06:30AM  
Sep-21-20 04:45PM  
Sep-03-20 04:30PM  
Aug-25-20 08:38AM  
06:30AM  
Aug-10-20 08:35AM  
07:00AM  
Aug-07-20 03:34PM  
Aug-03-20 12:31PM  
Jun-29-20 07:30AM  
Jun-18-20 08:00AM  
Jun-15-20 09:36PM  
May-27-20 08:00AM  
May-06-20 04:05PM  
Apr-29-20 04:15PM  
Apr-07-20 08:00AM  
Mar-17-20 08:00AM  
Feb-28-20 08:00AM  
Feb-27-20 04:05PM  
Feb-14-20 11:29AM  
Jan-08-20 12:00PM  
Nov-30-19 09:40AM  
Nov-18-19 04:15PM  
Nov-12-19 04:24PM  
Oct-30-19 10:35AM  
Aug-30-19 01:00PM  
Aug-12-19 06:30AM  
Jul-17-19 09:00AM  
Jul-01-19 04:30PM  
Jun-26-19 08:30PM  
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral av6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a47 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD). The company is also developing MR 6 #2, a selective av6 specific integrin inhibitor to treat IPF and PSC; and av1 integrin for the treatment of fibrosis. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrodinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics; and drug discovery research collaboration with HitGen Inc. to identify small molecule leads against targets specified by the company. The company was founded in 2014 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DeVaul WilliamGeneral Counsel and SecretaryAug 14Option Exercise4.321,2015,1883,701Aug 17 06:44 PM
DeVaul WilliamGeneral Counsel and SecretaryAug 14Sale30.341,20136,4402,500Aug 17 06:44 PM
DeVaul WilliamGeneral Counsel and SecretaryAug 13Option Exercise4.321,1044,7693,604Aug 17 06:44 PM
DeVaul WilliamGeneral Counsel and SecretaryAug 13Sale30.131,10433,2662,500Aug 17 06:44 PM
Lugovskoy AlexeyChief Development OfficerJul 09Sale24.9951312,818105,248Jul 09 07:32 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 08Option Exercise4.328563,6983,356Jul 09 07:31 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 08Sale24.8485621,2632,500Jul 09 07:31 PM
Lugovskoy AlexeyChief Development OfficerJul 08Sale24.883,63090,303105,761Jul 09 07:32 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 07Option Exercise4.321,2615,4483,761Jul 09 07:31 PM
Lugovskoy AlexeyChief Development OfficerJul 07Sale25.855,001129,265109,391Jul 09 07:32 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 07Sale25.951,26132,7182,500Jul 09 07:31 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 06Option Exercise4.322,2009,5044,700Jul 06 07:44 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 06Sale25.882,20056,9342,500Jul 06 07:44 PM
Lugovskoy AlexeyChief Development OfficerJul 06Sale25.874,304111,344114,392Jul 06 08:19 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 02Option Exercise4.325,40023,3287,900Jul 06 07:44 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 02Sale26.515,400143,1332,500Jul 06 07:44 PM
Lugovskoy AlexeyChief Development OfficerJul 02Sale26.4710,039265,734118,696Jul 06 08:19 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 01Option Exercise4.322,2839,8634,783Jul 06 07:44 PM
Lugovskoy AlexeyChief Development OfficerJul 01Sale26.544,513119,790128,735Jul 06 08:19 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 01Sale26.512,28360,5332,500Jul 06 07:44 PM
Rogers BruceChief Scientific OfficerJun 10Sale23.3325,000583,251153,319Jun 12 06:34 PM
Farrell Robert E JrSVP Finance and CAOJun 01Sale20.356,681135,97277,934Jun 01 07:10 PM
Farrell Robert E JrSVP Finance and CAOMay 29Sale20.1713,319268,67284,615Jun 01 07:10 PM
Rogers BruceChief Scientific OfficerMay 28Sale22.5520,000450,914178,319May 29 07:17 PM